Researchers from NUS Medicine report that the protein DUSP4 helps preserve CD8+ T-cell cancer-killing function against colorectal tumors. In preclinical models, boosting DUSP4 activity improved CAR-T cell performance, linking an immune-regulatory target to improved cellular therapy efficacy. The study frames DUSP4 as a lever for sustaining effector cell competence rather than solely increasing infiltration, an important distinction in the tumor microenvironment where T cells often lose functional activity. For CAR-T and cell-therapy developers, the finding supports engineering or pharmacologic modulation of DUSP4-linked signaling as a potential path to reduce functional exhaustion.